Novo Nordisk A/S v. Caraco Pharmaceutical Laboratories, Ltd.

DECISION RE: DOC. 318

AVERN COHN, District Judge.

This is a patent case involving the drug repaglinide marketed by Novo Nordisk (Novo) under the trade name Prandin. Now before the Court is Caraco Pharmaceutical Laboratories’ (Caraco) Motion for Summary Judgment on Count IV of Its Third Amended Counterclaim and Sixth Affirmative Defense for Patent Misuse (Dkt. 318). The background of the case as well as Caraco’s motion is described in the Court’s decisions reported at 450 F.Supp.2d 757 (E.D.Mich.2006) (finding allegations of complainant sufficient to state a claim against Sun) and 2009 WL…